This page has been archived on the Web
Information identified as archived is provided for reference, research or recordkeeping purposes. It is not subject to the Government of Canada Web Standards and has not been altered or updated since it was archived. Please contact us to request a format other than those available.
ACT Losartan / HCT (2017-09-01)
- Starting date:
- September 1, 2017
- Posting date:
- September 26, 2017
- Type of communication:
- Drug Recall
- Subcategory:
- Drugs
- Hazard classification:
- Type III
- Source of recall:
- Health Canada
- Issue:
- Product Safety
- Audience:
- Healthcare Professionals, General Public, Hospitals
- Identification number:
- RA-64606
Affected products
ACT Losartan / HCT
Reason
Out of specification for Hydrochlorothiazide assay in affected lot
Depth of distribution
wholesalers and retailers, including pharmacies within Canada
Affected products
ACT Losartan / HCT
DIN, NPN, DIN-HIM
02388278
Dosage form
Tablet
Strength
12.5mg - Hydrochlorothiazide
100mg - Losartan Potassium
Lot or serial number
K50626
Companies
- Recalling Firm
-
Teva Canada Limited
30 Novopharm Court
Toronto
M1B 2K9
Ontario
CANADA
- Marketing Authorization Holder
-
Teva Canada Limited
30 Novopharm Court
Toronto
M1B 2K9
Ontario
CANADA